News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Interim Report January - September 2012 Chrontech Pharma AB


10/26/2012 6:34:15 AM

· Research and development costs amounted to SEK 10.7 (10.5) m
· The loss after tax was SEK -14.9 (-13.9) m
· Earnings per share were SEK -0.08 (-0.14)
· The company had no net sales for the period
· The patient recruitment for the controlled phase II clinical study of ChronVac-C® in combination with standard-of-care is complete
· The development of ChronTech’s IVIN technology progresses according to plan

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES